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Interaction of misonidazole and WR-2721 II.
Modification of tumour radiosensitization
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Summary Two types of mouse tumour have been used to study the radiomodifying actions of Misonidazole
(MISO) and WR-2721 when used alone and in combination with each other. Single dose studies were
performed in both of the tumours and fractionated studies were performed on the anaplastic carcinoma, CA
MT. Radioprotection with WR-2721 was seen in both tumours, being most marked at low X-ray doses. The
protection was more obvious and the sensitization by MISO less in the fractionated experiment. The
combination of MISO and WR-2721 gave an intermediate response compared with either drug used alone,
resulting in some sensitization with single doses and an overall protection with repeated small doses. An
interactive toxicity of the 2 drugs was also observed, suggesting an additive effect when assessed in terms of
lethality. These studies indicate that the effects of both MISO and WR-2721 are dependent upon the oxygen
status of the cells in the tumour, and that MISO can act in an oxygen-mimetic manner to modify the
radioprotection observed with WR-2721.
We have studied the modification of the radiation
response of 2 mouse tumours by the radiosensitizer
Misonidazole (MISO) and the radioprotector WR-
2721, used alone or in combination. The purpose of
this was to determine whether WR-2721 interfered
with the tumour radiosensitizing effect of MISO,
and whether any therapeutic advantage could be
gained with the combination.
Radiosensitizers have been shown to enhance
tumour damage (Fowler & Denekamp, 1979) by
selectively increasing the radiosensitivity of hypoxic
cells (Adams, 1978). Radioprotectors, on the other
hand, are reputed to specifically protect normal
tissues (Yuhas, 1981) because of their greater
effectiveness on oxic than on hypoxic cells (Harris
& Phillips, 1971) and because of their preferential
uptake into normal tissues (Yuhas, 1980). Until
recently both, drugs have been considered selective
and specific in their mode of action. However, there
is cumulative experimental evidence that MISO can
cause slight sensitization of rodent normal tissues
(Hendry & Sutton, 1978; Stewart et al., 1982a), and
aminothiols like WR-2721 can protect some rodent
tumours, particularly at low X-ray doses (Utley et
al., 1974; Clement & Johnson, 1982; Rojas et al.,
1982a; Stewart et al., 1982b).
Because of their systemic toxicity only low doses
of each drug could be administered in clinical
radiotherapy. If the toxicities of the 2 drugs are not
additive, the possibility of combining low doses of
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MISO and WR-2721 seems one way of achieving a
therapeutic advantage. Previous work by Yuhas et
al. (1977) has shown that the combination was
advantageous compared with either drug used
alone. They claimed no additive lethal toxicity and
no interference by one agent in the radiomodifying
action of the other.
We have previously reported that in mouse skin
WR-2721 radioprotection is significantly decreased
in the presence of low doses of MISO (Rojas et al.,
1982b). This paper reports a similar effect in
tumours: Reduction of tumour radiosensitization
by MISO is seen if WR-2721 is present, both for
single doses and a 5-fraction schedule. Our tumour
and skin data are consistent with reports in the
literature from chemical and cellular studies, which
show interaction between certain radiosensitizers
(including oxygen) and sulphydryl radioprotectors.
These experimental results are interpreted as
competition between these compounds for
radiation-induced lesions, resulting in either fixation
or repair of damage to biological targets (e.g.
Chapman et al., 1973; Koch & Howell, 1980, 1981).
Materials and methods
Specific-pathogen free albino mice of the strain
WHT/Gy f BSVS were used in all experiments.
Animals were caged in groups of 4 and given free
access to food and water.
Tumours
Two experimental tumours of different kinetic and
histological characteristics were used.
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1) Fibrosarcoma SA FA a spontaneous tumour
which arose in this laboratory in 1974 and since
then has been serially transplanted in isogeneic
inbred mice. It is a moderately differentiated
fibrosarcoma with a doubling-time of about 4
days at 7mm mean diameter.
2) CA MT a rapidly growing anaplastic tumour
(originally a spontaneous mammary carcinoma)
with a doubling-time of about 1 day at 7mm
diameter.
Tumour fragments of mm were aseptically
transplanted s.c. into recipient mice using a simple
trocar technique under penthrane anaesthesia. The
SA FA was implanted on the ventral thorax, and
the CA MT on the sacral dorsum.
The animals were arbitrarily allocated to
different treatment groups when the tumours
reached a mean diameter of 7+1 mm. Each dose
group consisted of 4-15 animals, and the average
number available for analysis was 6 mice/group.
After irradiation, the tumours were measured
3 xweekly with vernier callipers. The mean tumour
diameter was calculated from 3 mutually
perpendicular measurements.
As a measure of radiation response, the time taken
to regrow to a specified size after irradiation was
determined for each individual tumour (radiation
size plus 4.5mm for the SA FA and plus 3.5mm
for CA MT). The regrowth delay was averaged for
individual animals in each dose group and plotted
with its standard error (s.e.) to give dose-response
curves. If an animal died or was sacrificed because
of metastases before the primary had reached the
regrowth size, it was included in the analysis with a
regrowth time equal to the time of death, provided
that its survival was equal to or greater than the
mean regrowth delay for the rest of the animals in
the same dose group. Locally-controlled tumours
were also included in the analysis and given an
arbitrary regrowth delay (Denekamp et al., 1980)
corresponding to the longest time at which
recurrence had ever been observed for that tumour
type (e.g. 75 days for CA MT). Such groups have
an upward arrow on their error bars, indicating
that the mean regrowth delay is a minimum
estimate.
Irradiation
X-rays at 240kV were generated in a Pantak X-ray
set. The beam was filtered with 0.25mmCu and
1.OmmAl (giving a HVL of 1.3mmCu); the dose
rate was 2.6Gymin 1 for SA FA and 3.2Gymin 1 for
the CA MT. The animals were turned half-way
through the irradiation to achieve a better dose
uniformity.
All irradiations were performed in air. For
experiments with the fibrosarcoma the animals were
anaesthetized 10min before irradiation with sodium
pentobarbitone (60mgkg-1 for animals receiving
no drug or MISO, and 40mgkg-1 for those
receiving WR-2721 alone or in combination with
MISO. This reduction in anaesthetic dose was
necessary to avoid toxicity.) The anaesthetized
animals bearing SA FA tumours were gently
restrained in a jig designed to shield the rest of
their body (Howes, 1969). The CA MT bearing
animals were irradiated without anaesthetic, using a
modified version of the tumour jig described by
Sheldon & Hill (1977).
Drugs
WR-2721 (S-2-(3-aminopropylamino)ethyl phos-
phorothioic acid) was kindly provided by the
Development Programme, Division of Cancer
Treatment, National Cancer Institute, Bethesda,
U.S.A. It was stored at -20°C, thawed and freshly
made up for each irradiation session. It was
dissolved in sterile distilled water at a concentration
corresponding to 0.3ml for a 30g mouse and
injected i.p. 30min before the start of irradiation.
Misonidazole (1-(2-nitroimidazole-1-yl)-3 meth-
oxypropan-2-ol) was kindly supplied by Roche
Products Ltd., Welwyn Garden City, Herts,
England. It was dissolved in sterile saline and 1 ml
per 30g mouse was given 45min before irradiation,
i.e. 15min before the radioprotector.
Results
Figure 1 illustrates experiments designed to
determine whether there was any additive toxicity
of the 2 drugs when used in combination. These
data represent single dose acute toxicity; the mice
usually died within 1-4 days after injection, but
survivors were observed for 30 days. In Figure la
the influence of 2 doses of MISO on the response
to graded doses of WR-2721 is shown. The WR-
2721 LD50level diminished from 1025 to
626mgkg-1 with increasing MISO dose. A similar
set of data for graded doses of MISO, in the
presence or absence of WR-2721 is shown in Figure
lb. Again a clear increase in toxicity is
demonstrated for the drug combination. These data
plus others are combined in Figure Ic as an
isobologram. There is a progressive decrease in the
LD50 dose of both drugs if a small quantity of the
other drug is added, indicating direct additive
toxicity. For all the points shown in Figure Ic WR-
2721 was administered 15min after MISO.
However a qualitatively similar but smaller effect
has been observed with intervals of 30, 45, 60 and
120min between the drugs (data not shown).MISO AND WR-2721 INTERACTION IN TUMOURS 67
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Figure 1 Drug toxicity assessed by animal survival at 30 days. The curves and LD50 values were obtained by
a logit fit to the data. 95% confidence limits are shown for LD50 values, except when they were smaller than
the symbols. (a) Lethality data for graded doses of WR-2721 given alone or 15min after the specified doses of
MISO. (b) Lethality data for graded doses of MISO given alone or 15min before the specified doses of WR-
2721. (c) Isobologram showing the LD50 dose of each drug in the absence or presence of specified doses of the
other.
Figure 2 shows the radiation response of the
fibrosarcoma to different treatments. Four curves
are shown: the response to X-rays alone, the
response in the presence of MISO alone, WR-2721
alone, or both drugs (heavy line). MISO was given
45min, and WR-2721 30min, before the start of
irradiation. The radioprotection observed with WR-
2721 was slight (PF* = 1.0-1.3), being less than that
reported in 2 earlier experiments (PF= 1.0-2.8)
using exactly the same experimental procedures in
this tumour (Stewart et al., 1982b). The reason for
this difference is not understood, but it seems likely
to be due to variation in the sensitivity to X-rays
alone, because of changes in the hypoxic fraction
between one transplant and another. Small doses of
MISO (200 mgkg-1) produced considerable
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Figure 2 Regrowth delay curves for SA FA as a function
of X-ray dose. Sensitization is seen with MISO, protection
with WR-2721 and little difference from X-rays alone if
both drugs are present.
X=X-rays alone. 0 =MISO 200mgkg- 1
O =WR-2721 600mgkg-1 * = MISO 200mgkg- 1 and
WR-2721 500mgkg- .
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Table I Sensitizer enhancement ratios for Misonidazole used alone or in combination with WR-2721
Tumour SA FA Tumour CA MT
Drug dose Days to regrow to R+4.5 mm Drug dose Days to regrow to R+3.5mm
(mg/kg) 28 40 (mgkg-') 28 40
Single dose
SER 200MISO 2.1±0.4 1.8+0.3 300MISO 1.7+0.4 1.9+0.3
SERPROT 200MISO 1.1+0.2 1.1+0.1 300MISO 1.3+0.3 1.4+0.2
plus plus
600WR 400WR
*SER 200MISO 1.6+0.3 1.8+0.2
*SERPROT 200MISO 1.2+0.2 1.2+0.1
plus
500WR
5 Fractions/4 days
SER 200MISO 1.4+0.2 1.1+0.2
SERPROT 200MISO 0.9+0.1 1.0+0.1
plus
250WR
The s.e. of the mean for the ratio have been computed as RMS values from the envelopes of errors on the growth delay
estimates.
*Repeat experiment - data not shown in Figure 2.
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Figure 3 Regrowth delay curves as a function of X-ray dose for single doses (a) and for 5 fractions in 4 days
(b). The protection with WR-2721 is most marked at low doses and the MISO sensitization is most
pronounced at high X-ray doses. The curve for both is intermediate, giving an overall sensitization with single
doses, but an overall protection with 5 fractions.
X=X-rays alone 0 = MISO 200-300mgkg-'
E]=WR-2721 250-400mgkg -' *=both MISO and WR-2721.
The higher drug doses were used in the single dose studies.
E
E
+ cr
C-
c
a
4-
0
cm
0
0
75MISO AND WR-2721 INTERACTION IN TUMOURS
enhancement of tumour damage (SERt=1.8-2.1).
When MISO was given in combination with the
protector, the tumour radiosensitization was
markedly reduced (SERprott=l.1). The same effect
was seen in a replicate experiment (data not
shown). The sensitization with MISO alone and
with WR-2721 present is summarised in Table I.
In Figure 3, similar dose response curves are
shown for the anaplastic CA MT for single dose
and 5 daily X-ray treatments. Regrowth delay from
the day of the first irradiation is plotted as a
function of the total X-ray dose. In the animals
that received WR-2721 considerable tumour
radioprotection was observed in both single and
fractionated schedules. PF values in each schedule
were highest at low X-ray doses, and are consistent
with WR-2721 protecting the oxic tumour cells
most efficiently. Tumour radiosensitization by
MISO was also considerable in this tumour,
particularly in the single dose schedule, and at high
X-ray doses where hypoxic cells determine the
radiation response. The effect of the sensitizer was
significantly decreased with fractionation
presumably because of reoxygenation (Table I).
When both drugs were given in combination,
tumour sensitization was again significantly
decreased, as summarised in Table I. This effect
was most dramatic in the 5-fraction group, where
sensitization was completely abolished and an
overall radioprotective effect was observed for the
drug combination.
The decrease in radiosensitization is illustrated in
Figure 4 where the MISO-induced sensitization is
expressed as a function of the added dose of WR-
2721. The vertical bars represent the range of SER
values calculated at different levels of regrowth
delay, usually from 28-40 days. The SER for MISO
alone was similar in the two tumours for single
doses of200-300mgkg-1, but was markedly lower in
the 5-fraction schedule. For all 3 experiments a
significant reduction in SER was demonstrated
when 250-600mgkg-' WR-2721 was combined with
MISO.
Discussion
These results show an interaction between MISO
and the aminothiol WR-2721, both in terms of drug
toxicity and of their radiomodifying effect on 2
:SERprot (SER with protector)
Dose of X-rays alone
Dose of X-rays+MISO+WR-2721
for equivalent regrowth delay.
1.0. ..
N
0.5
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Figure 4 The influence of WR-2721 on the sensitization
achieved with MISO. The open symbols represent single
dose studies, the closed symbols are for 5 daily fractions.
There is less sensitization with the fractionated studies. In
all cases the addition of WR-2721 reduces the
sensitization produced by MISO.
0, A =SA FA with 200mg/kg MISO single dose (2
experiments).
O =CA MT with 300mgkg1 MISO, single dose.
*=CA MT with 200mgkg1 MISO in 5 fractions.
mouse tumours. This is similar to the conclusions
previously drawn for mouse skin (Rojas et al.,
1982b).
Figure 1 shows that each drug enhances the
toxicity of the other, and the effect appears to be
directly additive. A non-toxic dose of MISO can
become extremely toxic in the presence of WR-2721
(Figure lb) and vice versa (Figure la). The death
from MISO alone or from the drug combination
usually occurred within 24h, and from WR-2721
alone within 72h. These toxicity data are in close
agreement with those reported by Grigsby &
Maruyama (1981), but contrast with the finding of
no additive toxicity by Yuhas et al. (1977).
The cause of death from these drugs, whether
used alone or in combination, is not known.
MISO is known to be neurotoxic (Dische et al.,
1978; Conroy et al., 1979) and induces hypothermia
(Gomer & Johnson, 1979). WR-2721 causes
vasodilation (Yuhas et al., 1973), hypotension in
some species, including man (Kligerman et al.,
1981), has ganglionic blocking activity (Caldwell &
Heiffer, 1975) and also induces hypothermia, as do
other SH compounds (Bacq, 1965).
Figures 2, 3 and 4 demonstrate clearly that WR-
2721 interferes with the radiosensitizing action of
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MISO in two mouse tumours. The decrease in
sensitization was similar for all 3 experiments, as
judged by the slope of the lines in Figure 4, even
though the initial magnitude of sensitization varied.
The radiomodifying effect of both drugs is
influenced by the inhomogeneous oxygenation of
tumour cells. It is of clinical significance, however,
that the overall effect with the combination only
tends towards sensitization at high X-ray doses,
and to tumour radioprotection at the low X-ray
doses used in both schedules (Figures 2 and 3).
At small, clinically relevant, X-ray doses the
radiosensitivity of tumours is determined by the
euoxic population, whereas at high doses the more
radioresistant hypoxic cells become predominant
(Fowler & Denekamp, 1979). Since MISO is
ineffective in the presence of oxygen, it affords little
sensitization at low X-ray doses; this is illustrated
by the decrease in SER because of reoxygenation
with the 5-fraction schedule (Figure 4). Conversely,
sulphydryls have been shown to be more effective
under euoxic conditions both in vitro and in vivo
(Alper, 1962; 1979; Bridges, 1962; Harris & Phillips,
1971; Wright, 1962). This results in more tumour
protection at low X-ray doses (Phillips et al., 1973;
Utley et al., 1974; Denekamp et al., 1982b). Thus
the decrease in radiosensitization with fractionation
was "mirrored" by an increase in radioprotection.
Recent studies, using epidermal clones in vivo, have
shown that the oxygen dependence of sulphydryl
radioprotection is complex and depends on the
precise oxygenation status, rather than simply on
whether the cells are euoxic or hypoxic (Denekamp
et al., 1981; 1982a). This agrees with in vitro studies
with other sulphydryls, in bacteria and mammalian
cells (Dewey, 1963; Cullen et al., 1980).
Our data contrast with the report by Yuhas et
al., (1977), who observed no reduction of
radiosensitization in the line 1 carcinoma when
WR-2721 was used in combination with MISO.
They observed a marked sensitization with
200mg/kg of MISO (SER=2.5) even at low X-ray
doses: This was not reduced by the addition of
400mg/kg of WR-2721. However, this carcinoma
appears to be an extremely fast growing and radio-
resistant tumour, since 20Gy caused growth delay
of only one day. If the tumour radioresistance
is the result of a large hypoxic fraction, it would
explain the sensitization by MISO at low doses, the
lack of radioprotection, and the negligible effect of
WR-2721 on MISO radiosensitization.
The interaction reported here for tumour
radiomodification resembles that which we have
previously shown for normal mouse skin (Rojas et
al., 1982b). In that tissue the WR-2721
radioprotection was significantly reduced in the
presence of MISO. A similar effect was observed
for oral mucosa (Grigsby & Maruyama, 1981) and
for bone marrow (Yuhas et al., 1977), but only a
small interaction was seen in skin (Yuhas et al.,
1977) and none was reported for salivary glands
(Sodicoff et al., 1979). The latter study however,
depends upon historical controls which may
compromise the conclusions.
We believe that the interaction we have observed
is a radiochemical effect rather than a physiological
or pharmacokinetic effect because it has also been
observed in normal tissues in vivo and for cells in
vitro. The hypothermia that is induced by both
drugs in mice could result in changes in blood flow
and hence in the oxygenation status of the tumour
cells. However the bulk of the experimental studies
on hypothermia indicate that the time course for
sulphydryl radioprotection does not match the time
course for development of hypothermia, and the
degree of hypothermia induced by the drug
combination would not be sufficient to produce
radioprotection through this mechanism. This topic,
which was once the subject of considerable
controversy, is well summarised by Scott (1963) and
Bacq (1965).
The competing effects of oxygen-mimetic
compounds and SH compounds have also been
widely documented in vitro (Chapman et al., 1973;
Asquith et al., 1974; Hall et al., 1977, Koch &
Howell, 1980, 1981). These data have been
interpreted as competition between oxidising and
reducing species for fixation and repair of radiation
induced radicals, as postulated in the oxygen-
fixation hypothesis (Alexander & Charlesby, 1954).
The present data, together with most of the
published studies indicate that MISO and WR-2721
are not independent in their radiomodifying action,
either on tumours or on normal tissues. In
addition, there is obviously an interaction in terms
of lethal toxicity. Thus, there does not appear to be
a firm basis for expecting that the combination of
small doses of both drugs will give any therapeutic
advantage over their use as single agents.
Furthermore, the oxygen dependency of both the
radioprotective and radiosensitizing agents means
that for clinical relevance, experiments must be
performed at appropriate X-ray doses because the
population under treatment contains a mixture of
euoxic and hypoxic cells. Since the pattern of
reoxygenation will determine the proportion of
hypoxic cells at the time of each irradiation, more
fractionated experiments are needed. Studies
performed only with large single doses of X-rays
may be misleading.
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